University College Dublin
Dublin, Ireland
NCT Number: NCT03429491
This study will examine the effect of leucine-enriched protein supplementation, alone and in combination with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), on muscle mass and function in older adults at risk of sarcopenia.
The investigators hypothesize that LC n-3 PUFA supplementation will further enhance the efficacy of the leucine-enriched protein.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Dublin, Ireland
The progressive loss of skeletal muscle mass and function with advancing age, termed sarcopenia, contributes substantially to disability, physical dependence, and mortality among older adults. Aging is associated with an attenuated muscle protein synthetic response to the ingestion of small to moderate protein doses compared to younger persons. Several studies have reported that the acute, postprandial muscle protein synthesis (MPS) response to a suboptimal protein dose is enhanced when the leucine content of the protein bolus is increased. This indicates that supplementing the lower-protein daily meals (i.e., breakfast and lunch) with leucine may represent a practical strategy to augment the MPS response to these meals and, subsequently, attenuate sarcopenic muscle mass loss over time. In addition, LC n-3 PUFA supplementation has been shown to enhance the MPS response to amino acid infusion older adults suggesting that combined leucine and LC n-3 PUFA supplementation be particularly effective for improving daily MPS, muscle mass and function in older adults.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Protein-free, LC n-3 PUFA-free juice based supplement
Leucine-enriched whey protein
LC n-3 PUFA
Time frame: 6 months
Assessed via dual energy x-ray absorptiometry
Time frame: 6 months
Maximal voluntary contraction
Time frame: 6 months
Short physical performance battery, single leg stand, timed up and go
Time frame: 6 months
Assessed using nuclear magnetic resonance (NMR) spectroscopy
Time frame: 6 months
Assessed via RNA Sequencing
Time frame: 6 months
Assessed in dominant leg via MRI in sub cohort (n=39)
Time frame: 6 months
Measured as fractional synthetic rate (%/day) over a 3-d period at baseline and end of study
University College Dublin
Other
Novel Nutrition Solutions in Elderly at Risk of Sarcopenia: LC n-3 PUFA and Leucine Combinations
Acronym: NUTRIMAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT06629805
Atrophy, Muscular Atrophy
Yangsan, South Korea
View Trial DetailsNCT07629063
Atrophy, Basal Ganglia Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07716839
Aging, Atrophy
Montes Claros, Minas Gerais, Brazil
View Trial Details